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medical and prescription claims collected over a 4-year study period (January 1, 
2001–December 31, 2004) from more than 300,000 employees. Data from employees 
with and without (controls) functional dyspepsia were compared using 2-part regres-
sion techniques. Outcome measures included direct and indirect costs paid by the 
employer, absenteeism, direct costs by the place of service where care was performed, 
and objectively measured productivity output. RESULTS: Employees with functional 
dyspepsia (N = 1669) had greater average annual direct medical and prescription drug 
costs and indirect costs (due to sick leave, short- and long-term disability absences) 
than controls (N = 274,206). Compared with controls, the functional dyspepsia 
employees incurred health beneﬁt costs that were $5,138 greater and had greater costs 
for each place of service (all P < 0.0001). The employees with functional dyspepsia 
had an additional 0.83 absence days per year and produced 12% fewer units per hour 
than controls (both P < 0.05). CONCLUSIONS: Employees with functional dyspepsia 
have greater costs at all places of service and lower productivity than employees 
without functional dyspepsia.
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OBJECTIVES: The aim of this study was to estimate the annual societal disease 
burden of irritable bowel syndrome (IBS) in Korea for the year of 2008. METHODS: 
The claim data with IBS were extracted from the Health Insurance Review & Assess-
ment Service database in 2008 of Korea. After deﬁnition of patient with specialists, 
the prevalence and medical costs were calculated. The number of outpatient visits and 
length of hospital stay also were calculated to estimate transportation cost and pro-
ductivity loss. RESULTS: The annual national patients with IBS were estimated to 
1.30 million with 753,688 (57.79%) for female. The results showed that the 
crude prevalence of IBS was 2.68% (95%CI: 2.66%-2.71%, 2.25% for male and 
3.12% for female) in 2008. The total cost due to IBS was 14.9 billion won (1$ = 
1047.30 won, 2008) including 348 million won for direct medical cost (2.33%), 88 
million won for nonmedical cost (transportation costs), and 14.5 billion won for lost 
work due to illness. CONCLUSIONS: The disease burden of IBS appears to be high 
because of the high morbidity although not a signiﬁcant cause of death. The result is 
likely to underestimate due to using claim data and strict deﬁnition of patient. 
However, this data might be useful and necessary to support evidence based decision 
making for IBS.
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OBJECTIVES: To compare direct and indirect costs between HCV patients on 
pegylated interferon with ribavirin (PEG-RBV), untreated HCV, and non-HCV con-
trols. METHODS: We identiﬁed three cohorts using the MarketScan Commercial 
Claims and Encounters Database® from 2002–2007: HCV patients on PEG-RBV, 
untreated HCV, and non-HCV controls. We used propensity scores to match treated 
to untreated (1:1), and HCV to non-HCV patients (1:3). We compared direct costs 
and utilization across the cohorts. We performed subset analysis using the MarketScan 
Health and Productivity Management Database® to evaluate absenteeism and short-
term disability costs. RESULTS: We identiﬁed 10,001 PEG-RBV patients. Compared 
to untreated patients, treated patients had higher total medical costs ($28,547 vs. 
$21,752; p < 0.001) outpatient pharmacy costs ($17,419 vs. $2,900; p < 0.001) and 
outpatient physician visit costs ($894 vs. $787; p < 0.001), but lower inpatient costs 
($3,942 vs. $9,543; p < 0.001) and ER costs ($366 vs. $505; p < 0.001). Treated 
patients had similar absenteeism rates (93% vs. 88%; p = 0.27), higher short-term 
disability rates (33% vs. 30%;p < 0.001) and higher indirect costs ($11,528 vs. 
$9,316; p < 0.05). Non-HCV controls had signiﬁcantly lower costs in all categories 
compared to patients with HCV. Total costs among matched non-HCV costs were 
$15,932, outpatient pharmacy costs were $1,796, outpatient physician visit costs were 
$429, inpatient costs were $2,181, and ER costs were $184; indirect costs were 
$7,654. After adjusting for demographic and clinical characteristics, including HIV 
and cirrhosis, differences remained signiﬁcant but diminished. CONCLUSIONS: HCV 
patients engender a higher economic burden compared to non-HCV controls. Treated 
patients cost more than untreated patients; the cost differential is primarily driven by 
higher outpatient pharmacy costs. Indirect cost differences are driven by greater 
absenteeism duration and greater short term disability use and duration. These data 
provide insight into the economic burden of HCV and its treatment, and may be 
employed in future health economic analyses evaluating existing and emerging 
therapies.
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OBJECTIVES: To document variations in resource utilization and costs by disease 
severity, sustained viral response (SVR), and genotype in a European population with 
chronic hepatitis C virus (C-HCV). METHODS: Patient charts from the UK, France, 
Germany, Spain, and Italy were retrospectively reviewed. Inclusion criteria were: 
C-HCV diagnosis within past 5 years; age ≥18 years; no diagnoses of hepatitis B or 
HIV/AIDS; ≥1 year follow-up post-diagnosis; no clinical trial participation. All-cause 
utilization and costs (2009 3) for hospitalizations, emergency room (ER) and ofﬁce 
visits, and specialty referrals were aggregated within patients over 1 year post-diag-
nosis. C-HCV severity was assessed via Metavir score. Among patients receiving 
C-HCV-directed pharmacotherapy, SVR was deﬁned by viral RNA < 10 IU/mL at ≥6 
months post-treatment. Utilization and cost differences across clinical factors were 
assessed with multivariate modeling. RESULTS: In total, 1016 patients were identi-
ﬁed. Overall, 23% of severe patients were hospitalized versus 2.5% of mild. Hospi-
talization was 5 times more likely in severe C-HCV compared to mild (odds ratio 
[OR] = 5.39; P = 0.008), while the hospitalization rate, measured by Poisson incidence 
rate ratio (IRR), was 4 times higher (IRR = 3.98; P = 0.010). Hospital costs were 
31380 higher in severe versus mild disease (P = 0.001). Hospitalization risk in SVR 
attainers was less than half that of non-attainers (OR = 0.22; P < 0.0001). ER, ofﬁce, 
and specialist visit rates were signiﬁcantly lower among SVR attainers. Genotype had 
little effect on utilization, but genotype 1 was associated with slightly lower (390 per 
patient; P < 0.0001) hospital costs versus genotypes ≥2. CONCLUSIONS: Disease 
severity and SVR are important predictors of C-HCV costs. Awareness of these factors 
by public health systems, which bear the high cost burden of C-HCV, may help 
promote strategies for earlier disease detection and increased treatment initiation 
before progression occurs, as well as formulary access for more convenient therapies 
that increase treatment persistence and thereby SVR rates.
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OBJECTIVES: Assess patterns of utilization and costs of twice daily 24 mcg dosing 
of lubiprostone in a large managed care population. METHODS: Patients included 
Humana members 18 years and older with medical claims for chronic constipation 
(CC) and/or irritable bowel syndrome (IBS) between April 1, 2006 and April 30, 2008. 
The index date was the ﬁrst diagnosis of CC or IBS. Patients had at least 180-days of 
continuous enrollment pre-index and at least 30-days post-index. Users and non-users 
were compared. Users were compared pre- and post-lubiprostone initiation. RESULTS: 
A total of 92,804 patients with a diagnosis of CC or IBS were identiﬁed during the 
study period; 1873 ﬁlled at least one 30-day prescription for lubiprostone. Seventy-ﬁve 
percent of users were female. Lubiprostone users were younger than non-users (61.6 
vs. 66.2 yrs old) and more likely to be co-prescribed opiates (35.5 vs. 29.4%), anti-
histamines (14.8 vs. 9.5%) and tricyclic antidepressants (8.1 vs. 4.7%), all statistically 
signiﬁcant. Common co-morbidities in lubiprostone users were back problems 
(23.6%) and abdominal pain (21.9%). A total of 1605 users had both 6-months pre- 
and post-lubiprostone initiation data. A total of 42.2% of these patients ﬁlled more 
than one 30-day lubiprostone prescription; 6.42% ﬁlled 6 or more. Usage of other 
prescription laxatives decreased by 4.6% (p < 0.05) subsequent to lubiprostone initia-
tion. Monthly health care costs per utilizing member increased by $67.10 (p < 0.0001). 
Pharmacy costs rose by $71.73 (p < 0.0001) and ER costs decreased by $8.12 (p < 
0.05). Pre-post changes in outpatient and inpatient costs were not signiﬁcant. Monthly 
inpatient and ER visits for these 1605 members decreased by 0.31 and 0.08 per utiliz-
ing member respectively (p < 0.05) in the 6-months after starting lubiprostone. 
Changes in outpatient visits were not signiﬁcant. CONCLUSIONS: Lubiprostone 
users were younger females who were co-prescribed opiates and had back problems. 
Higher health care costs were offset by a decrease in ER costs.
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Hepatitis C affects approximately 180 million people worldwide and is one of the 
main causes of chronic liver disease. HCV infection progresses to chronicity in approx-
imately 80% of infected individuals, from whom up to 20% can develop cirrhosis 
over 20 years, thus presenting high risk of complications related to hepatic insufﬁ-
ciency and/or hepatocellular carcinoma. OBJECTIVES: To compare treatment costs 
and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both associated 
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with ribavirin, in the therapeutic scheme of 24 weeks for hepatitis C genotype 2/3 in 
Brazilian Public Health System (SUS). METHODS: To project disease progression, a 
Markov model was built based on clinical stages of chronic disease. A Delphi panel 
was conducted to evaluate direct medical resources related to each stage, followed by 
micro-costing of the results. Perspective was from a public payer. Source used for 
costing was government reimbursement procedures list (SAI/SIH–SUS). Drug acquisi-
tion costs for a 70 kg patient were obtained from ‘Banco de Preços em Saúde’, govern-
ment ofﬁcial source. Costs were reported in 2009 Brazilian Reais (US$1≈$Brz1.7). 
Efﬁcacy of pegylated-interferons was obtained from a meta-analysis of 7 RTCs com-
paring the drugs, detailed elsewhere. For genotype 2/3, median rate of sustained 
virological response was 79.2% for peginterferon-alfa-2a and 73.8% for peginter-
feron-alfa-2b. Discount rate for costs and outcomes was 5%, according to Brazilian 
guidelines for HTA. RESULTS: Assuming a lifetime perspective, expected costs and 
outcomes for peginterferon-alfa-2a were $Brz15,898, 15.21LYs and 14.57QALYs; for 
peginterferon-alfa-2b, $Brz18,439, 15.11LYs and 14.32QALYs. Cost-effectiveness 
analysis estimated an ICER of -$Brz25,289/LY and -$Brz10,426/QALYs for peginter-
feron-alfa-2a, being the dominant therapy. For each 1000 patients treated with 
peginterferon-alfa-2a instead of peginterferon-alfa-2b, savings granted can be up to 
$Brz2,5 million which would allow treatment of 160 more patients. CONCLUSIONS: 
These ﬁndings suggest that treatment with peginterferon-alfa-2a is more effective and 
less costly when compared to peginterferon-alfa-2b under SUS perspective in Brazil.
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Chronic hepatitis C affects approximately 180 million people worldwide being one of 
the main causes of chronic liver disease. About 20% of patients with chronic hepatitis 
C can develop cirrhosis over 20 years, thus presenting risk of developing hepatic 
complications. Treatment is currently based on pegylated-interferon-alfa-2a or alfa-2b 
plus ribavirin. Sustained virologic response (SVR) is associated with a better prognosis 
compared to untreated patients and treatment failures. OBJECTIVES: To compare 
treatment costs and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, 
both plus ribavirin, in the therapeutic scheme of 48 weeks for hepatitis C genotype 1 
in Brazilian Public Health System (SUS). METHODS: To project disease progression, 
a Markov model was built based on clinical stages of chronic disease. A Delphi panel 
was conducted to evaluate direct medical resources related to each stage, followed by 
micro-costing of results. Perspective was from a public payer. Costing was based on 
government reimbursement procedures list (SAI/SIH–SUS). Drug acquisition costs 
(70 kg patient) were obtained from ‘Banco de Preços em Saúde’, government source. 
Costs were in 2009 Brazilian Reais (US$1≈$Brz1.7). Efﬁcacy of pegylated-interferons 
was obtained from a meta-analysis of 7 RTCs comparing the drugs, detailed else-
where. For genotype 1, SVR median rate was 42.1% for peginterferon-alfa-2a and 
33.3% for peginterferon-alfa-2b. Discount rate (costs and outcomes) was 5%, accord-
ing to Brazilian guidelines for HTA. RESULTS: Assuming a lifetime perspective, 
expected costs and outcomes for peginterferon-alfa-2a were $Brz36,713, 14.51LYs 
and 12.89QALYs; for peginterferon-alfa-2b $Brz41,191, 14.35LYs and 12.49QALYs 
gained. Cost-effectiveness analysis estimated an ICER of -$Brz27,266/LY and 
-$Brz11,277/QALY for peginterferon-alfa-2a, being the dominant therapy. For each 
1000 patients treated with peginterferon-alfa-2a instead of peginterferon-alfa-2b, 
savings granted can be up to $Brz4,4 million which would allow treatment of 120 
more patients. CONCLUSIONS: Findings suggest that treatment with peginterferon-
alfa-2a is more effective and less costly when compared to peginterferon-alfa-2b under 
SUS perspective in Brazil.
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Hepatitis C affects approximately 180 million people worldwide and is currently one 
of the main causes of chronic liver disease. HCV infection progresses to chronicity in 
up to 80% of infected individuals, from whom approximately 20% progress to cir-
rhosis over 20 years. These individuals are at risk of developing hepatic failure and/
or hepatocellular carcinoma. OBJECTIVES: To compare treatment costs and out-
comes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both associated with 
ribavirin, in the therapeutic scheme of 24 weeks for hepatitis C in Brazilian private 
market for the treatment of HCV infection genotypes 2/3. METHODS: To project 
disease progression, a Markov model was built based on clinical stages of chronic 
disease. A Delphi panel was conducted to evaluate direct medical resources related to 
each stage, followed by micro-costing of the results. The perspective was from a private 
payer. Source used for costing was medical society physicians fee list (CBHPM-2008). 
Drug acquisition costs for a 70kg patient were obtained from ofﬁcial public sources 
(Kairos Magazine-Nov2009). Costs were reported in 2009 Brazilian Reais 
(US$1≈$Brz1.7). Efﬁcacy of pegylated-interferons was obtained from a meta-analysis 
of 7 RCTs comparing the drugs, detailed elsewhere. For genotype 2/3, median rate of 
sustained virological response was 79.2% for peginterferon-alfa-2a and 73.8% for 
peginterferon-alfa-2b. Discount rate for costs and outcomes was 5%, according to 
Brazilian guidelines for HTA. RESULTS: Assuming a lifetime perspective, expected 
costs and outcomes for peginterferon-alfa-2a were $Brz48,363, 15.21LYs and 
14.57QALYs; for peginterferon-alfa-2b, $Brz52,154, 15.11 LYs and 14.32QALYs. 
Cost-effectiveness analysis estimated an ICER of -$Brz37,614/LY and -$Brz15,556/
QALYs for peginterferon-alfa-2a, being the dominant therapy. For each 1000 patients 
treated with peginterferon-alfa-2a instead of peginterferon-alfa-2b, savings granted 
can be up to $Brz3,8 million which would allow treatment of 78 more patients. 
CONCLUSIONS: These ﬁndings suggest that treatment with peginterferon-alfa-2a is 
more effective and less costly when compared to peginterferon-alfa-2b under private 
payer perspective in Brazil.
PGI21
ECONOMIC ANALYSIS OF ALVIMOPAN FOR PREVENTION AND 
MANAGEMENT OF POST-OPERATIVE ILEUS
Yang Y1, Touchette DR1, Tiryaki F1, Galanter W2
1University of Illinois at Chicago, Chicago, IL, USA, 2The University of Illinois at Chicago, 
Chicago, IL, USA
OBJECTIVES: Whether the use of alvimopan is cost-effective, compared to the stand-
ard post-operative care, for post-operative ileus (POI) among patients undergoing 
small- or large-bowel resection via laparotomy. METHODS: We constructed a formal 
decision model from the health care system perspective. The clinical outcomes (time 
to discharge order written [DCO], post-operative nasogastric tube insertion, POI-
related readmission within 7 days, nausea and vomiting) were obtained from meta-
analyses of published studies. Cost inputs included costs associated with the drugs, 
nursing labor, readmission, and hospitalization. Cost-consequence was assessed by 
determining the net cost of alvimopan use and subsequent reduction in length of stay 
(LOS). Sensitivity analyses were conducted. RESULTS: The alvimopan drug cost was 
$570 based on an average of 9.5 doses. Given the 18.4-hour mean reduction in DCO, 
the use of alvimopan reduced hospitalization costs by $2021. In the base-case, alvi-
mopan resulted in a $1187 per-person cost savings. In sensitivity analyses, the result 
was robust to changes in key parameters including the cost and number of doses of 
alvimopan, DCO, readmission rates, and hospitalization cost. In scenario analyses, 
alvimopan use yielded a cost saving of $897 when no difference in readmission rates 
was assumed. However, when no difference in DCO was asssumed, the total cost of 
care with alvimopan was $278 greater. Similarly, it was $569 greater when both 
readmission rates and DCO were assumed to be equal between strategies. In Monte 
Carlo simulation, the mean difference in overall cost of care was $1252 (95% certainty 
interval: -$398 to $6306), favoring the use of alvimopan. CONCLUSIONS: The 
overall hospitalization cost reduction associated with the use of alvimopan offsets the 
drug cost. Alvimopan appears to be cost-saving for POI among patients undergoing 
bowel resection via laparotomy. This ﬁnding is not applicable to the less-invasive 
laparoscopic surgical approach which has been associated with decreased post-oper-
ative morbidity and LOS.
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OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness of entecavir 
and telbivudine in HBeAg-positive/-negative chronic hepatitis B (CHB) patients based 
on the ability of each drug to suppress viral replication. METHODS: A cost-effective-
ness analysis was performed to evaluate the impact of treatment on disease morbidity 
and costs over the lifetime and the short term (10 years) for a patient based on a 
societal perspective. A decision tree was developed to assess the drug abilities to sup-
press HBV DNA replication. To obtain probability estimates with HBV DNA levels 
and resistance rates of entecavir and telbivudine, recent entecavir-lamivudine BEHoLD 
studies and telbivudine-lamivudine GLOBE studies were indirectly compared. The 
risks of progression to compensated cirrhosis (CC), decompensated cirrhosis (DC), or 
HCC were derived from the REVEAL-HBV study, which was to evaluate the relation-
ship between hepatitis B viremia and progression to cirrhosis and HCC. For the life 
expectancy of DC and HCC, the declining exponential approximation of life (DEALE) 
method was applied based on the published annual mortality rates of DC and HCC. 
Both direct and indirect medical costs were included and univariate sensitivity analyses 
were performed on parameters in the model to evaluate the impact of parameter 
uncertainty. RESULTS: On a per-person basis, the ICERs of entecavir compared to 
telbivudine for lifetime therapy were $13,649 and $52,776 in HBeAg-positive and 
HBeAg-negative CHB, respectively. In the 10-year model, the ICERs were $US 39,089 
and $US 365,100 in HBeAg-positive and HBeAg-negative CHB, respectively. One-way 
sensitivity analyses showed that the model was robust to most parameters. However, 
parameters such as drug costs, discount rate and average time to events from study 
entry were sensitive. CONCLUSIONS: For lifetime therapy and for HBeAg-positive 
patients, entecavir was cost effective compared to telbivudine. However, in the short-
term treatment model for HBeAg-negative CHB, entecavir was not cost-effective.
